175 related items for PubMed ID: 31851145
1. Platelet Count Variation and Risk for Coronary Artery Abnormalities in Kawasaki Disease.
Ae R, Abrams JY, Maddox RA, Schonberger LB, Nakamura Y, Shindo A, Kuwabara M, Makino N, Matsubara Y, Kosami K, Sasahara T, Belay ED.
Pediatr Infect Dis J; 2020 Mar; 39(3):197-203. PubMed ID: 31851145
[Abstract] [Full Text] [Related]
2. Analysis of Age, Sex, Lack of Response to Intravenous Immunoglobulin, and Development of Coronary Artery Abnormalities in Children With Kawasaki Disease in Japan.
Takekoshi N, Kitano N, Takeuchi T, Suenaga T, Kakimoto N, Suzuki T, Kada TT, Shibuta S, Tachibana S, Murayama Y, Yamaga H, Suzuki H.
JAMA Netw Open; 2022 Jun 01; 5(6):e2216642. PubMed ID: 35696166
[Abstract] [Full Text] [Related]
3. Correlation of Coronary Artery Abnormalities with Fever Pattern in Patients with Kawasaki Disease.
Tanaka A, Inoue M, Hoshina T, Koga H.
J Pediatr; 2021 Sep 01; 236():95-100. PubMed ID: 34019881
[Abstract] [Full Text] [Related]
4. Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease.
Chantasiriwan N, Silvilairat S, Makonkawkeyoon K, Pongprot Y, Sittiwangkul R.
Paediatr Int Child Health; 2018 Aug 01; 38(3):209-212. PubMed ID: 29768976
[Abstract] [Full Text] [Related]
5. Epidemiological and Clinical Characteristics of Kawasaki Disease and Factors Associated with Coronary Artery Abnormalities in East China: Nine Years Experience.
Tang Y, Gao X, Shen J, Sun L, Yan W.
J Trop Pediatr; 2016 Apr 01; 62(2):86-93. PubMed ID: 26884440
[Abstract] [Full Text] [Related]
6. A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?
Li W, He X, Zhang L, Wang Z, Wang Y, Lin H, Yuan J, Xie X, Qin Y, Huang P.
Cardiovasc Ther; 2021 Apr 01; 2021():6660407. PubMed ID: 34239607
[Abstract] [Full Text] [Related]
7. Immunoglobulin G values before treatment are correlated with the responsiveness to initial intravenous immunoglobulin therapy for Kawasaki disease.
Yanagimoto K, Nomura Y, Masuda K, Hirabayashi M, Morita Y, Yoshishige M, Ueno K, Eguchi T, Kawano Y.
Int Arch Allergy Immunol; 2014 Apr 01; 164(2):83-8. PubMed ID: 24903098
[Abstract] [Full Text] [Related]
8. Treatment change and coronary artery abnormality in incomplete Kawasaki disease.
Nomura Y, Yashiro M, Masuda K, Nakamura Y.
Pediatr Int; 2020 Jul 01; 62(7):779-784. PubMed ID: 32219919
[Abstract] [Full Text] [Related]
9. Effect of different doses of aspirin on the prognosis of Kawasaki disease.
Wang J, Chen H, Shi H, Zhang X, Shao Y, Hang B, Xu Z, Rong X, Chu M, Qiu H.
Pediatr Rheumatol Online J; 2020 Jun 11; 18(1):48. PubMed ID: 32527316
[Abstract] [Full Text] [Related]
10. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
Pediatrics; 2004 Dec 11; 114(6):e689-93. PubMed ID: 15545617
[Abstract] [Full Text] [Related]
11. A Multicenter Study of Intravenous Immunoglobulin Non-response in Kawasaki Disease.
Wei M, Huang M, Chen S, Huang G, Huang M, Qiu D, Guo Z, Jiang J, Zhou X, Yu Q, Guo Y, Fu L, Gao W, Li F.
Pediatr Cardiol; 2015 Aug 11; 36(6):1166-72. PubMed ID: 25812827
[Abstract] [Full Text] [Related]
12. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM, Silverman ED, McCrindle BW, Yeung RS.
J Pediatr; 2002 Apr 11; 140(4):450-5. PubMed ID: 12006960
[Abstract] [Full Text] [Related]
13. Risk factors for coronary artery abnormalities in children with Kawasaki disease: a 10-year experience.
Maric LS, Knezovic I, Papic N, Mise B, Roglic S, Markovinovic L, Tesovic G.
Rheumatol Int; 2015 Jun 11; 35(6):1053-8. PubMed ID: 25429794
[Abstract] [Full Text] [Related]
14. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.
Pediatr Infect Dis J; 2008 Feb 11; 27(2):155-60. PubMed ID: 18174868
[Abstract] [Full Text] [Related]
15. Factors affecting the duration of coronary artery lesions in patients with the Kawasaki disease: a retrospective cohort study.
Zhang X, He Y, Shao Y, Hang B, Xu Z, Chu M.
Pediatr Rheumatol Online J; 2021 Jun 26; 19(1):96. PubMed ID: 34174872
[Abstract] [Full Text] [Related]
16. Relationship between post-IVIG IgG levels and clinical outcomes in Kawasaki disease patients: new insight into the mechanism of action of IVIG.
Goto R, Inuzuka R, Shindo T, Namai Y, Oda Y, Harita Y, Oka A.
Clin Rheumatol; 2020 Dec 26; 39(12):3747-3755. PubMed ID: 32458247
[Abstract] [Full Text] [Related]
17. Seasonal Variation in Epidemiology of Kawasaki Disease-Related Coronary Artery Abnormalities in Japan, 1999-2017.
Kitano N, Takeuchi T, Suenaga T, Kakimoto N, Naka A, Shibuta S, Tachibana S, Takekoshi N, Suzuki T, Tsuchihashi T, Yamano T, Akasaka T, Suzuki H.
J Epidemiol; 2021 Feb 05; 31(2):132-138. PubMed ID: 32092750
[Abstract] [Full Text] [Related]
18. Clinical relevance of the risk factors for coronary artery lesions in Kawasaki disease.
Weng KP, Hsieh KS, Huang SH, Ou SF, Ma CY, Ho TY, Lai CR, Ger LP.
Kaohsiung J Med Sci; 2012 Jan 05; 28(1):23-9. PubMed ID: 22226058
[Abstract] [Full Text] [Related]
19. Association between intravenous immunoglobulin dose and outcomes in patients with acute Kawasaki disease.
Michihata N, Suzuki T, Yoshikawa T, Saito K, Matsui H, Fushimi K, Yasunaga H.
Eur J Pediatr; 2022 Oct 05; 181(10):3607-3615. PubMed ID: 35925450
[Abstract] [Full Text] [Related]
20. Blood routine risk factors for coronary artery aneurysm in infants younger than 8 months with Kawasaki disease.
Haiyan G, Jianming L, Suqian T, Dong Q, Shuang L, Jin Z.
BMC Pediatr; 2022 Jan 07; 22(1):29. PubMed ID: 34996405
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
